15
Participants
Start Date
February 6, 2023
Primary Completion Date
July 25, 2024
Study Completion Date
July 25, 2024
Next-generation Reader and ID-Cap System
The digital pill system (DPS) is comprised of an ingestible radiofrequency emitter, integrated into a standard gelatin capsule, which then over-encapsulates the study medication (PrEP or ART). On ingestion, the radiofrequency emitter is activated by chloride ions in the stomach, projecting a signal approximately three feet off the body. This radio signal is acquired by a wearable device (Reader) which stores and forwards data to a smartphone, enabling on-demand access to adherence data. The next-generation Reader is a wrist-borne device.
Truvada for pre-exposure prophylaxis (PrEP)
Participants will ingest one Truvada digital pill as PrEP per day, for 30 days total.
Biktarvy for antiretroviral therapy (ART)
Participants will ingest one Biktarvy digital pill as ART per day, for 30 days total.
Fenway Health, Boston
The Fenway Institute
OTHER
Brigham and Women's Hospital
OTHER